Harrow Health, Inc.
NASDAQ:HROWDrug Manufacturers - Specialty & Generic
+$0.12 today
- Market cap
- $1.21B
- Beta
- 0.28
- P/E (TTM)
- -104.7
- EPS (TTM)
- -$0.40
Volume 0.87M
Average 0.75M
HROW EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Harrow Health, Inc.NASDAQ: HROW
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$16.5M, compared with -$6.69M a year earlier. Trailing-twelve-month EBITDA was $31.47M.
Context
- EBITDA amounted to 15.2% of revenue in FY2025, up 4.1 pp from a year earlier.
- EBITDA increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 7 analysts of $49.79M (+20.4%) for the fiscal year ending Dec 2026, a slowdown from the +86.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$16.5M-181.0% QoQ
- Last fiscal yearDec 2025
- $41.36M+86.9% YoY
- LTMMar 2026
- $31.47M+78.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -146.4% | -65.2% | +81.2 pp |
| 1 year | +86.9% | +20.4% | -66.6 pp |
| 3-year CAGR | — | +93.3% | — |
| 5-year CAGR | +65.5% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 41.36M USD
- Year-over-year change
- +86.9%
- 4-year CAGR
- +68.7%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 41.36M | +86.9% |
| FY2024 | 2024-12-31 | 22.13M | +85.2% |
| FY2023 | 2023-12-31 | 11.95M | +403.6% |
| FY2022 | 2022-12-31 | (3.94M) | -177.1% |
| FY2021 | 2021-12-31 | 5.1M | — |
EBITDA vs competitors
How HROW compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +78.4% is the highest of 8, against a peer median of -55.5%.
- EBITDA amounts to 11.7% of revenue for HROW, versus a peer median of 1971.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $742M USD | +61.3% | -3.6% | 13.9% | |
| LTM Mar 2026 | $31.47M USD | +78.4% | — | 11.7% | |
TTRXTurn Therapeutics Inc. | LTM Mar 2026 | -$3.79M USD | — | — | — |
| LTM Mar 2026 | -$62.08M USD | -482.8% | — | 18634.1% | |
| LTM Mar 2026 | -CHF 94.13M CHF | +7.5% | — | 18676.3% | |
| LTM Sep 2026 | -$225.15M USD | -18.0% | — | — | |
| LTM Mar 2026 | -$260.06M USD | -79.4% | — | 3415.1% | |
| LTM Mar 2026 | -$274.24M USD | -55.5% | — | 527.0% | |
| LTM Sep 2026 | -$686.8M USD | -845.4% | — | 100.7% | |
| Peer median (excluding HROW) | — | -55.5% | -3.6% | 1971.1% | |
Competitors are the stored peer set for HROW. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 72.48M | 88.6M | 130.19M | 199.61M | 272.3M |
| Cost of Revenue | 18.21M | 25.38M | 39.64M | 49.25M | 67.93M |
| Gross Profit | 54.26M | 63.21M | 90.55M | 150.37M | 204.37M |
| Gross Margin | 74.9% | 71.3% | 69.6% | 75.3% | 75.1% |
| Research & Development | 11.08M | 3.05M | 6.65M | 12.23M | 12.85M |
| Selling, General & Admin | 39.82M | 0 | 0 | 0 | 152.91M |
| Operating Expenses | 52.65M | 61.29M | 90.12M | 141.55M | 165.76M |
| Depreciation & Amortization | 1.74M | 2.83M | 11.14M | 13.05M | 18.91M |
| EBITDA | 5.1M | (3.94M) | 11.95M | 22.13M | 41.36M |
| EBITDA Margin | 7.0% | -4.4% | 9.2% | 11.1% | 15.2% |
| Operating Income | 1.61M | 1.92M | 431K | 8.82M | 38.61M |
| Operating Margin | 2.2% | 2.2% | 0.3% | 4.4% | 14.2% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 5.44M | 7.24M | 21.32M | 22.79M | 24.18M |
| Other Income / Expenses | (19.49M) | (15.93M) | (24.14M) | (26.14M) | (40.33M) |
| Income Before Tax | (17.87M) | (14.01M) | (23.71M) | (17.32M) | (1.72M) |
| Pre-Tax Margin | -24.7% | -15.8% | -18.2% | -8.7% | -0.6% |
| Income Tax Expense | 133K | 75K | 701K | 161K | 3.42M |
| Net Income | (18.01M) | (14.09M) | (24.41M) | (17.48M) | (5.14M) |
| Net Margin | -24.8% | -15.9% | -18.7% | -8.8% | -1.9% |
| EPS (Basic) | (0.69) | (0.51) | (0.75) | (0.49) | (0.14) |
| EPS (Diluted) | (0.69) | (0.51) | (0.75) | (0.49) | (0.14) |
| Weighted Avg Shares | 26.76M | 27.46M | 32.62M | 35.65M | 36.76M |
| Weighted Avg Shares (Diluted) | 26.76M | 27.46M | 32.62M | 35.65M | 36.76M |
Harrow Health, Inc.
NASDAQ:HROW
Intrinsic Alpha fair value
Locked
Current Price
$32.16
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.